Rhoh deficiency reduces peripheral T‐cell function and attenuates allogenic transplant rejection

TL;DR

Rhoh deficiency in mice attenuates acute and chronic kidney allograft rejection and improves graft function, largely through intrinsic defects in peripheral T-cell activation, cytokine release, and cytotoxicity rather than altered dendritic cell function or lower T-cell numbers alone. The paper proposes Rhoh as a potential target for suppressing T-cell-mediated transplant rejection.

Key findings

• In murine allogenic kidney transplantation, Rhoh deficiency caused a significant 75% reduction of acute and chronic transplant rejection, 75% lower alloantigen-specific antibody levels, and significantly better graft function.
• When equal numbers of Rhoh-deficient or control T cells were injected into kidney-transplanted SCID mice, Rhoh-deficient T cells still caused a significant 60% reduction of rejection, indicating the effect was not solely due to lower peripheral T-cell numbers.
• Mixed lymphocyte reaction showed 85% lower cytotoxicity and 50–80% lower cytokine release in Rhoh-deficient T cells, without an influence on secretion itself; antigen uptake and presentation by dendritic cells were unaffected.
• Rhoh-deficient T cells showed weaker CD69 upregulation, cytokine secretion, proliferation, and cytotoxicity after TCR stimulation, but no general secretory defect after TCR-independent PMA/A23187 stimulation.

Methods

• Allogenic BALB/c→C57BL/6 kidney transplantations were performed in bilaterally nephrectomized Rhoh-deficient and control recipients, with syngenic C57BL/6→C57BL/6 transplants as controls; grafts were evaluated at days 7, 21, and 42. SCID recipients received equal numbers (1×10^7) of purified Rhoh-deficient or control T cells immediately after transplantation.
• In vitro assays included mixed lymphocyte reactions with equal T cells and T cell-depleted BALB/c stimulators, TCR-dependent stimulation with plate-bound anti-CD3 ± anti-CD28, TCR-independent stimulation with PMA and Ca²⁺ ionophore A23187, cytotoxicity assays, BMDC antigen uptake/presentation assays, flow cytometry, and cytokine bead arrays.
• Histology, immunohistochemistry/immunofluorescence, creatinine clearance, and alloreactive antibody titers were assessed; statistical comparisons used two-tailed unpaired Student’s t-test or Mann-Whitney test, with p<0.05 considered significant.

Limitations

• The paper states that a deranged mast cell phenotype cannot be ruled out completely as contributing to ameliorated rejection, although SCID experiments with wild-type myeloid cells indicated mast cells were not a prominent contributor.
• The paper does not include a dedicated limitations section; evident limitations include the use of a mouse renal allograft model without immunosuppressive therapy, global Rhoh deficiency rather than T-cell-specific deletion, and heterozygous Rhoh+/− controls rather than wild-type controls (though the paper states their phenotype did not differ from wild-type).
• The mechanistic in vitro assays rely on purified splenic T cells and BMDC, so the findings may not fully capture all cell-cell interactions in the transplant microenvironment.